{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:43:58Z","timestamp":1794865438131,"version":"4.9.1"},"reference-count":25,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,24]]},"DOI":"10.1182\/bloodadvances.2025015981","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T19:13:15Z","timestamp":1744225995000},"page":"3026-3030","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":23,"title":["Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myeloma"],"prefix":"10.1182","volume":"9","author":[{"given":"Joshua N.","family":"Gustine","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3868-9267","authenticated-orcid":false,"given":"Andrew R.","family":"Branagan","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5719-581X","authenticated-orcid":false,"given":"Diana D.","family":"Cirstea","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2797-956X","authenticated-orcid":false,"given":"Farah","family":"Rexha","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8821-2689","authenticated-orcid":false,"given":"Ryan","family":"Han","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3623-7491","authenticated-orcid":false,"given":"Andrew J.","family":"Yee","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7578-0393","authenticated-orcid":false,"given":"Marcela V.","family":"Maus","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frigault","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noopur S.","family":"Raje","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"issue":"18","key":"2025062410414672400_bib1","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"2025062410414672400_bib2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"2025062410414672400_bib3","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"10297","key":"2025062410414672400_bib4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"2025062410414672400_bib5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"2025062410414672400_bib6","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.119.044362","article-title":"Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis","volume":"141","author":"Bick","year":"2020","journal-title":"Circulation"},{"issue":"2","key":"2025062410414672400_bib7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"2025062410414672400_bib8","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"issue":"26","key":"2025062410414672400_bib9","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood.2020008206","article-title":"Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis","volume":"136","author":"Miller","year":"2020","journal-title":"Blood"},{"issue":"7709","key":"2025062410414672400_bib10","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"issue":"suppl 1","key":"2025062410414672400_bib11","doi-asserted-by":"crossref","first-page":"246.5","DOI":"10.4049\/jimmunol.204.Supp.246.5","article-title":"De novo DNA methylation programs regulate CAR T-cell exhaustion","volume":"204","author":"Zebley","year":"2020","journal-title":"The J Immunol"},{"issue":"1","key":"2025062410414672400_bib12","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1038\/s41467-020-16805-5","article-title":"Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant","volume":"11","author":"Mouhieddine","year":"2020","journal-title":"Nat Commun"},{"issue":"9","key":"2025062410414672400_bib13","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/s41375-018-0208-8","article-title":"Clonal hematopoiesis in patients with multiple myeloma undergoing autologous stem cell transplantation","volume":"32","author":"Chitre","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"2025062410414672400_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2025062410414672400_bib15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1001\/jamacardio.2023.4105","article-title":"Clonal hematopoiesis and cardiovascular disease in patients with multiple myeloma undergoing hematopoietic cell transplant","volume":"9","author":"Rhee","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"8","key":"2025062410414672400_bib16","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"2025062410414672400_bib17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"15","key":"2025062410414672400_bib18","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1182\/bloodadvances.2021004554","article-title":"Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy","volume":"5","author":"Miller","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"2025062410414672400_bib19","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1182\/bloodadvances.2021005747","article-title":"Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment","volume":"6","author":"Teipel","year":"2022","journal-title":"Blood Adv"},{"issue":"10","key":"2025062410414672400_bib20","doi-asserted-by":"crossref","first-page":"e957","DOI":"10.1097\/HS9.0000000000000957","article-title":"Clinical implications and dynamics of clonal hematopoiesis in anti-CD19 CAR T-cell treated patients","volume":"7","author":"Panagiota","year":"2023","journal-title":"Hemasphere"},{"issue":"7","key":"2025062410414672400_bib21","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy","volume":"6","author":"Kambhampati","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2025062410414672400_bib22","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","article-title":"The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"16","author":"Rejeski","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"9","key":"2025062410414672400_bib23","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas dos Santos","year":"2024","journal-title":"Nat Med"},{"issue":"12","key":"2025062410414672400_bib24","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/2767-9764.CRC-23-0093","article-title":"Clinical outcomes and evolution of clonal hematopoiesis in patients with newly diagnosed multiple myeloma","volume":"3","author":"Mouhieddine","year":"2023","journal-title":"Cancer Res Commun"},{"issue":"21","key":"2025062410414672400_bib25","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.1182\/bloodadvances.2023012522","article-title":"Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma","volume":"8","author":"Palacios-Berraquero","year":"2024","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/12\/3026\/2380078\/blooda_adv-2025-015981-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/12\/3026\/2380078\/blooda_adv-2025-015981-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T14:47:27Z","timestamp":1750776447000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/12\/3026\/536663\/Impact-of-clonal-hematopoiesis-on-clinical"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,6,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025015981","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6,24]]},"published":{"date-parts":[[2025,6,16]]}}}